A significant volume of new M&A deals during 2021 are expected to involve cell and gene therapy developers as in recent years—but with an emerging twist resulting from some recent clinical disappointments for autologous treatments . . .
EY Firepower Report: Biopharma M&A Poised to Rebound in 2021
Value of mergers and acquisitions predicted to return to historical average but fall short of 2019
Source: John Lund/Getty Images
